Showing results (151-160 of 157) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.Lung Cancer (Amsterdam, Netherlands)|January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerJianhua Chang, Yi-Long Wu, Shun Lu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.The Lancet. Oncology|June 21, 2013
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialYi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, et al.Hepatology International|August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapyGeorge Lau, Ming-Lung Yu, Grace Wong, et al.Nature Medicine|April 29, 2020
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.Nature Medicine|June 20, 2020
Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancerYou Lu, Jianxin Xue, Tao Deng, et al.Pageof 16